Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. [electronic resource]
Producer: 20191021Description: 679-686 p. digitalISSN:- 2152-2669
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bendamustine Hydrochloride -- administration & dosage
- Drug Resistance, Neoplasm -- drug effects
- Female
- Follow-Up Studies
- Humans
- Isoquinolines -- administration & dosage
- Lymphoma, B-Cell -- drug therapy
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Recurrence, Local -- drug therapy
- Prognosis
- Prospective Studies
- Rituximab -- administration & dosage
- Salvage Therapy
- Survival Rate
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.